Results 31 to 40 of about 36,486 (260)

Patient reported goals for medications for opioid use disorder: A theory of proximal goal attainment

Exploratory Research in Clinical and Social Pharmacy, 2023
Background: There exist substantial patient barriers to accessing medications for opioid use disorder (MOUD), including travel distance, stigma, and availability of MOUD providers.
Kenneth C. Hohmeier, Alina Cernasev, Christina Leibold, Todd M. Moore, Erica Schlesinger, Ileana Arce, Wesley Geminn, Marie Chisholm-Burns, Gerald Cochran   +8 more
doaj   +1 more source

Health disparities in chronic liver disease

Hepatology, EarlyView., 2022
Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew   +3 more
wiley   +1 more source

Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial

Addiction Science & Clinical Practice, 2021
Telemedicine (TM) enabled by digital health technologies to provide medical services has been considered a key solution to increasing health care access in rural communities.
Yih-Ing Hser, Allison J. Ober, Alex R. Dopp, Chunqing Lin, Katie P. Osterhage, Sarah E. Clingan, Larissa J. Mooney, Megan E. Curtis, Lisa A. Marsch, Bethany McLeman, Emily Hichborn, Laurie S. Lester, Laura-Mae Baldwin, Yanping Liu, Petra Jacobs, Andrew J. Saxon   +15 more
doaj   +1 more source

Review of medication-assisted treatment for opioid use disorder

Journal of Osteopathic Medicine, 2022
Abstract Context The American opioid epidemic has necessitated the search for safe and effective means of treatment for opioid use disorder (OUD). Medication-assisted treatment (MAT) encompasses select medications that are proven effective treatments for OUD.
Nessreen, Ghanem, Devin, Dromgoole, Ahmad, Hussein, Richard T, Jermyn   +3 more
openaire   +2 more sources

Recovery capital among people receiving treatment for opioid use disorder with buprenorphine

Harm Reduction Journal, 2021
Background Recovery is a multidimensional process that includes health, quality of life, and citizenship. Recovery capital is a strengths-based concept representing the sum of an individual’s resources that support recovery.
Anna Beth Parlier-Ahmad, Mishka Terplan, Dace S. Svikis, Laura Ellis, Caitlin E. Martin   +4 more
doaj   +1 more source

Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial

BMC Public Health, 2021
Background A key strategy for mitigating the current opioid epidemic is expanded access to medications for treating opioid use disorder (MOUD). However, interventions developed to expand MOUD access have limited ability to engage opioid users at higher ...
Dennis P. Watson, James A. Swartz, Lisa Robison-Taylor, Mary Ellen Mackesy-Amiti, Kim Erwin, Nicole Gastala, Antonio D. Jimenez, Monte D. Staton, Sarah Messmer   +8 more
doaj   +1 more source

COVID‐19: A new barrier to treatment for opioid use disorder in the emergency department

Journal of the American College of Emergency Physicians Open, 2021
Objective Start Treatment and Recover (STAR) is an emergency department (ED) program that expands access to medication for opioid use disorder by identifying patients with opioid use disorder and offering ED‐initiated buprenorphine/naloxone and rapid ...
Warren Grunvald, Ramsey Herrington, Roz King, Miles Lamberson, Scott Mackey, Sanchit Maruti, Richard Rawson, Daniel Wolfson   +7 more
doaj   +1 more source

Medication for Adolescents and Young Adults With Opioid Use Disorder [PDF]

Journal of Adolescent Health, 2021
Opioid-related morbidity and mortality have risen in many settings globally. It is critical that practitioners who work with adolescents and young adults (AYAs) provide timely, evidence-based treatment for opioid use disorder (OUD). Such treatment should include medications for opioid use disorder (MOUD), including buprenorphine, naltrexone, and ...
openaire   +2 more sources

Hospitalization Through Families’ Eyes: Comparing Inpatient Care Quality for Children With Sickle Cell Disease and Cystic Fibrosis in Canada

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Sickle cell disease (SCD) is a chronic, inherited hemoglobinopathy that requires frequent hospitalization for disease‐related complications. Canadian data on inpatient care is limited. This study compared caregiver‐reported hospital experiences of children with SCD to those with cystic fibrosis (CF), a chronic, autosomal recessive ...
Hailey M. Zwicker, Kyle Kemp, Perri Tutelman, Sharon H. J. Hou, Paul Fairie, Maria Santana, Gregory M. T. Guilcher, Taryn Fay‐McClymont, Glenda Bendiak, Wendy Pelletier, Nicola Wright, Fiona Schulte   +11 more
wiley   +1 more source

U.S. student pharmacist perceptions of the pharmacist’s role in methadone for opioid use disorder: A qualitative study

SAGE Open Medicine, 2021
Background: Of the over 20 million Americans reporting an opioid use disorder, only around 3 million report receiving treatment of any kind. The gold standard for opioid use disorder treatment is medication in combination with psychosocial support, but ...
Kenneth C Hohmeier, Alina Cernasev, Megan Sensmeier, Elizabeth Hall, Katie Webb, Rachel Barenie, Gerald Cochran   +6 more
doaj   +1 more source